Library · Skin & hair · Skin regeneration and collagen synthesis enhancement
CT-388
CT388, Cyclic Tripeptide 388, CT 388
Dual GLP-1/GIP receptor agonist in Phase 2 development by Roche/Carmot Therapeutics for obesity and type 2 diabetes. Early data suggest strong weight loss and glucose control, similar to other dual agonists like tirzepatide.
Research score 80/100. Reference only, not a dose.
- Skin Health
- Collagen Production
- Wound Healing
- Anti-aging
- US status
- Research Chemical
- Approval
- Research Chemical Only
- Evidence
- Phase 1/2 trials ongoing. Dual GLP-1/GIP agonist.
- Research score
- 80 / 100
- Indication
- Research Only - No Medical Indication
- Origin
- USA
- Source category
- Skin & Dermatology
- Status group
- Research chemical
Mechanism
The published mechanism text for this entry describes a different compound, so it is left out here.
Safety file
Consistent with other incretin drugs; mainly GI effects, with no unexpected safety signals in early trials.
- Mild skin irritation
- Temporary redness
- Contact dermatitis in sensitive individuals